A vaccine scandal in China, which has prompted angry reactions from citizens fed up with safety scares, is sending ripples across the local drug market and threatening Chinese ambitions to play a larger role in the global pharmaceutical space.

Regulators said last week they had halted production of a rabies vaccine made by Changchun Changsheng Life Sciences Limited, which is based in north-eastern China, after finding fabricated records and other problems during an inspection.

By today, shares in Chinese vaccine makers and biotech firms had fallen across the board.

The Premier slammed the company late yesterday for having crossed a moral red line and called for swift action.



Please enter your comment!
Please enter your name here